Jintao He

TL;DR: The data reveals that the pathway ‘HULC/USP22/Sirt1/ protective autophagy’ attenuates the sensitivity of HCC cells to chemotherapeutic agents, suggesting that this pathway may be a novel target for developing sensitizing strategy to HCC chemotherapy.

TL;DR: It is demonstrated for the first time that HULC promoted the growth of HCC cells through elevating COX-2 protein through the role of ubiquitin-specific peptidase 22 (USP22), and the identification of this novel pathway may pave a road for developing new potential anti-HCC strategies.

TL;DR: A novel NIR small-molecule autophagy-enhancer, IR-58, with mitochondria-targeted imaging and therapy capabilities was developed for CRC treatment and TIM44 was identified for the first time as a potential oncogene, which plays an important role in Autophagy through the TIM44-SOD2-ROS-mTOR pathway.

TL;DR: It is found that DCA and Met synergistically inhibited the growth and enhanced the apoptosis of ovarian cancer cells and may pave a way for developing novel strategies for the treatment of ovariancancer based on the combined use ofDCA and metformin.

TL;DR: The results demonstrate for the first time that the phosphorylation of ATG4B at Ser34 participates in the metabolic reprogramming of HCC cells via repressing mitochondrial function, which possibly results from the Ser34 phosphorylations-induced mitochondrial enrichment of ATg4B and the subsequent inhibition of F1Fo-ATP synthase activity.